French National Registry of Children Born Small for Gestational Age Treated With Somatropin
NCT ID: NCT01578135
Last Updated: 2022-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
291 participants
OBSERVATIONAL
2007-03-18
2018-10-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
NCT01580605
Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)
NCT00597480
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
NCT01973244
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
NCT05308927
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
NCT00557336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I
somatropin
Patients are to fill in a questionnaire at inclusion in registry
Phase II
somatropin
Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
somatropin
Patients are to fill in a questionnaire at inclusion in registry
somatropin
Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Paris La Défense, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GHSGA-1757
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.